STOCK TITAN

Royalty Pharma plc (RPRX) SEC Filings, Jun-Aug 2026

RPRX NASDAQ

Royalty Pharma plc filings document the company’s biopharmaceutical royalty business, public equity structure, governance, financing activity, and material events. Form 8-K reports furnish quarterly and annual results, including Portfolio Receipts, Royalty Receipts, operating cash flow, guidance, dividends, and developments affecting royalty and funding arrangements.

Regulation FD and material-agreement disclosures describe royalty transactions, synthetic royalty funding, senior secured loan arrangements, and portfolio-related clinical or regulatory events. Other filings cover Class A ordinary shares listed on Nasdaq, senior note issuances and related guarantees, annual meeting matters, board and compensation governance, shareholder voting items, and changes involving directors or officers.

Rhea-AI Summary

Royalty Pharma plc executive Urist Marshall reported two insider equity movements. He received 8,252 Class A Ordinary Shares as an exempt award tied to Equity Performance Awards and indirectly made a bona fide gift of 3,000 limited partnership interests exchangeable into 30,000 Class A shares. He also holds Class A shares indirectly through an IRA and Class E Ordinary Shares that are exchangeable into 1,356,528 Class A shares, subject to vesting conditions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.11%
Tags
insider
-
Rhea-AI Summary

Royalty Pharma plc reported total income and other revenues of $674,141 thousand for the quarter and $1,304,717 thousand for the six months ended June 30, 2026, driven mainly by income from financial royalty assets. Six‑month net income attributable to Royalty Pharma plc increased to $312,572 thousand from $271,525 thousand, with basic and diluted EPS of $0.71.

Operating cash flow for the first half rose to $1,446,694 thousand, while $707,587 thousand was used in investing activities, largely for $703,387 thousand of acquisitions of financial royalty assets. Cash and cash equivalents were $811,986 thousand against total debt of $8,961,892 thousand. Financial royalty assets, net, were $17,082,171 thousand. Results reflected a $69,443 thousand impairment on the Tazverik royalty, higher R&D funding expense of $137,641 thousand, and $229,648 thousand of share‑based compensation tied to the 2025 internalization. Shareholder returns included two $0.235 per‑share dividends totaling $209,406 thousand and repurchase of 2.0 million Class A shares for approximately $95.6 million.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.47%
Tags
quarterly report
-
Rhea-AI Summary

Royalty Pharma plc reported second quarter 2026 results and raised full-year 2026 guidance for Portfolio Receipts. Portfolio Receipts were $773 million, up 6%, and Royalty Receipts were $768 million, up 14%, driven by Tremfya, Voranigo, Imdelltra and Evrysdi. Net cash provided by operating activities doubled to $728 million. Adjusted EBITDA and Portfolio Cash Flow each reached $736 million, reflecting payments for operating and professional costs at 4.8% of Portfolio Receipts.

The company now expects 2026 Portfolio Receipts of $3,400 million to $3,500 million, versus $3,325 million to $3,450 million previously, implying expected Royalty Receipts growth of 7% to 10%. Cash and cash equivalents were $812 million and total debt principal was $9.2 billion as of June 30, 2026; a $380 million term loan was repaid in July. Capital Deployment was $349 million in the quarter, including royalty funding for daraxonrasib and R&D funding for JNJ‑4804 and litifilimab. Net income attributable to Royalty Pharma plc was $18 million compared with $32 million a year earlier.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.47%
Tags
current report
Rhea-AI Summary

Royalty Pharma plc EVP of Research & Investments Marshall Urist reported an open-market sale of 9,099 Class A Ordinary Shares. The shares were sold on July 1, 2026 at a weighted average price of $55.8802 per share in multiple trades within a disclosed price range. The filing states that all reported transactions were made under a pre-arranged Rule 10b5-1 trading plan adopted on February 12, 2026. After this sale, Urist reports no directly held Class A shares and an indirect holding of 19,020 shares through an IRA.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.47%
Tags
insider
-
Rhea-AI Summary

Royalty Pharma plc executive Christopher Hite reported pre-planned open-market sales of 130,000 Class A Ordinary Shares on June 30, 2026 under a Rule 10b5-1 trading plan. The sales occurred at weighted average prices generally between about $56 and $57 per share.

After these transactions, Hite holds 40,000 Class A Ordinary Shares directly. Additional shares are held indirectly through SCH Investment Partners LLC, which reported post-transaction ownership of 459,399 Class A Ordinary Shares. Some of the sales in this filing were executed by that LLC rather than by Hite personally.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.47%
Tags
insider
-
Rhea-AI Summary

Royalty Pharma plc officer Marshall Urist reported a proposed sale of 9,099 common shares, with an aggregate market value of $508,453.82 and an approximate sale date of July 1, 2026. Merrill Lynch is named as broker. The Rule 10b5-1 plan adoption or instruction date is February 12, 2026.

Separately, Marshall Urist acquired 9,099 Class A Ordinary Shares on May 8, 2026, through an Equity Performance Award granted as part of Royalty Pharma plc’s equity compensation program.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.57%
Tags
other
Rhea-AI Summary

Royalty Pharma plc is named in a notice for a proposed sale by SCH Investment Partners LLC of 100,000 Class A ordinary shares, with an aggregate market value of $5,709,000 and an approximate sale date of June 30, 2026. SCH Investment Partners LLC is listed under the issuer relationship “Officer.” The shares were acquired from the issuer in a private transaction on February 14, 2025. The proposed sales are in connection with a selling plan dated March 20, 2026, intended to comply with Rule 10b5-1(c). Christopher Hite signed the notice.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.52%
Tags
other
-
Rhea-AI Summary

Bassler Bonnie L reported acquisition or exercise transactions in this Form 4 filing.

Royalty Pharma plc director Bonnie L. Bassler received an award of 689 Class A Ordinary Shares, valued at $54.3998 per share. The shares were issued under the company’s 2020 Independent Director Equity Incentive Plan in lieu of a quarterly cash retainer of $37,500.

After this equity award, Bassler directly holds 79,181 Class A Ordinary Shares. This transaction reflects compensation paid in stock rather than cash, and does not represent an open-market purchase or sale.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.52%
Tags
insider
-
Rhea-AI Summary

Royalty Pharma plc EVP Marshall Urist reported an open-market sale of 9,098 Class A Ordinary Shares of RPRX at a weighted average price of $55.1843 per share. After this transaction, he directly holds 9,099 shares. The filing notes the sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on February 12, 2026, meaning the trades were scheduled in advance rather than timed discretionarily.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.82%
Tags
insider
Rhea-AI Summary

Royalty Pharma plc executive Christopher Hite reported pre-planned insider sales linked to an affiliated entity. On June 23, 2026, SCH Investment Partners LLC, an entity associated with Hite, sold a total of 150,000 Class A Ordinary Shares in open-market transactions at weighted average prices of $54.47 and $54.11 per share.

All transactions were executed under a Rule 10b5-1 trading plan adopted on March 20, 2026, indicating they were scheduled in advance. Following these sales, SCH Investment Partners LLC held 559,399 Class A Ordinary Shares indirectly for Hite, while he also held 70,000 shares directly.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.82%
Tags
insider

FAQ

How many Royalty Pharma plc (RPRX) SEC filings are available on StockTitan?

StockTitan tracks 138 SEC filings for Royalty Pharma plc (RPRX), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for Royalty Pharma plc (RPRX)?

The most recent SEC filing for Royalty Pharma plc (RPRX) was filed on November 18, 2026.